Skip to main navigation Skip to search Skip to main content

Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review

Marco Solmi, Alessandro Miola, Federico Capone, Simone Pallottino, Mikkel Højlund, Joseph Firth, Dan Siskind, Richard I G Holt, Olivier Corbeil, Samuele Cortese, Elena Dragioti, Ebba Du Rietz, René Ernst Nielsen, Merete Nordentoft, Paolo Fusar-Poli, Catharina A Hartman, Anne Høye, Ai Koyanagi, Henrik Larsson, Kelli LehtoPeter Lindgren, Mirko Manchia, Karolina Skonieczna-Żydecka, Brendon Stubbs, Davy Vancampfort, Eduard Vieta, Heidi Taipale, Christoph U Correll, ECNP Physical And meNtal Health Thematic Working Group (PAN-Health)

19 Citations (Scopus)

Abstract

INTRODUCTION: People with severe mental illness have poor cardiometabolic health. Commonly used antidepressants and antipsychotics frequently lead to weight gain, which may further contribute to adverse cardiovascular outcomes.

AREAS COVERED: We searched MEDLINE up to April 2023 for umbrella reviews, (network-)meta-analyses, trials and cohort studies on risk factors, prevention and treatment strategies of weight gain associated with antidepressants/antipsychotics. We developed 10 clinical recommendations.

EXPERT OPINION: To prevent, manage, and treat antidepressant/antipsychotic-related weight gain, we recommend i) assessing risk factors for obesity before treatment, ii) monitoring metabolic health at baseline and regularly during follow-up, iii) offering lifestyle interventions including regular exercise and healthy diet based on patient preference to optimize motivation, iv) considering first-line psychotherapy for mild-moderate depression and anxiety disorders, v)choosing medications based on medications' and patient's weight gain risk, vi) choosing medications based on acute vs long-term treatment, vii) using effective, tolerated medications, viii) switching to less weight-inducing antipsychotics/antidepressants where possible, ix) using early weight gain as a predictor of further weight gain to inform the timing of intervention/switch options, and x) considering adding metformin or glucagon-like peptide-1 receptor agonists, or topiramate(second-line due to potential adverse cognitive effects) to antipsychotics, or aripiprazole to clozapine or olanzapine.

Original languageEnglish
JournalExpert Opinion on Drug Safety
Volume23
Issue number10
Pages (from-to)1249-1269
Number of pages21
ISSN1474-0338
DOIs
Publication statusPublished - Oct 2024

Keywords

  • Obesity
  • antidepressant
  • antipsychotic
  • bipolar disorder
  • depression
  • psychiatry
  • safety
  • schizophrenia
  • weight gain

Fingerprint

Dive into the research topics of 'Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review'. Together they form a unique fingerprint.

Cite this